Abstract

We aimed to predict molecular subtypes of breast cancer using radiomics signatures extracted from synthetic mammography reconstructed from digital breast tomosynthesis (DBT). A total of 365 patients with invasive breast cancer with three different molecular subtypes (luminal A + B, luminal; HER2-positive, HER2; triple-negative, TN) were assigned to the training set and temporally independent validation cohort. A total of 129 radiomics features were extracted from synthetic mammograms. The radiomics signature was built using the elastic-net approach. Clinical features included patient age, lesion size and image features assessed by radiologists. In the validation cohort, the radiomics signature yielded an AUC of 0.838, 0.556, and 0.645 for the TN, HER2 and luminal subtypes, respectively. In a multivariate analysis, the radiomics signature was the only independent predictor of the molecular subtype. The combination of the radiomics signature and clinical features showed significantly higher AUC values than clinical features only for distinguishing the TN subtype. In conclusion, the radiomics signature showed high performance for distinguishing TN breast cancer. Radiomics signatures may serve as biomarkers for TN breast cancer and may help to determine the direction of treatment for these patients.

Highlights

  • We aimed to predict molecular subtypes of breast cancer using radiomics signatures extracted from synthetic mammography reconstructed from digital breast tomosynthesis (DBT)

  • Exclusion criteria were: (1) patients who received chemotherapy before DBT (n = 114), (2) patients who received surgical excision or vacuum-assisted biopsy (n = 41), (3) asymmetries that were only visible on a single view (n = 40), (4) diffuse infiltrative lesions involving the whole breast (n = 7), (5) lesions partially masked by a marker (n = 15), (6) lesions not fully included on synthetic mammography (n = 34), and (7) lesions not clearly delineated on synthetic mammography (n = 75)

  • This study revealed that the TN subtype of breast cancer can be distinguished by radiomics analysis of synthetic mammography reconstructed from DBT

Read more

Summary

Introduction

We aimed to predict molecular subtypes of breast cancer using radiomics signatures extracted from synthetic mammography reconstructed from digital breast tomosynthesis (DBT). The radiomics signature showed high performance for distinguishing TN breast cancer. A few studies have shown that radiomics features obtained from magnetic resonance imaging (MRI) can be associated with the molecular subtypes of breast ­cancer[14,15,16]. Mammography is the primary modality for breast cancer diagnosis and can be performed in all patients while being highly accessible. Being able to predict molecular subtype by routinely performed mammography will be of clinical value, and several previous studies have shown the p­ ossibilities[17,18]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call